Want to see IDXGD full AI Analyst Report?
Top Page
Interpace Diagnostics Group
(OTC:IDXGD)
Select Model
Select Model
Rating:63Neutral
Price Target:
$7.50
▲(413.70% Upside)
Action:Reiterated
Date:08/28/26
The score is driven mainly by improved fundamentals—profitability and balance-sheet strength with low leverage and positive cash generation. Offsetting this, technicals are notably weak (price below key moving averages with negative MACD) and the financial profile has a clear risk flag in declining revenue and weakening cash conversion in TTM, which makes the very low P/E less convincing as a standalone positive.
Positive Factors
Improved profitability
The shift to sustained operating profitability provides a stronger base for funding laboratory operations and product development. If maintained, improved earnings can support financial resilience, although the quality and durability of those earnings still require monitoring.
Negative Factors
Declining revenue base
A shrinking revenue base can weaken operating leverage, limit investment capacity, and signal pressure on test volumes, reimbursement, or customer adoption. Sustained contraction would make recent profitability harder to preserve and reduce visibility into the company’s durable growth profile.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved profitability
The shift to sustained operating profitability provides a stronger base for funding laboratory operations and product development. If maintained, improved earnings can support financial resilience, although the quality and durability of those earnings still require monitoring.
Read all positive factors
Interpace Diagnostics Group (IDXGD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.30M
Dividend YieldN/A
Average Volume (3M)2.75K
Price to Earnings (P/E)<0.1
Beta (1Y)1.66
Revenue Growth-20.48%
EPS Growth537.47%
CountryUS
Employees102
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)5.38
Shares Outstanding5,540,181
10 Day Avg. Volume5,306
30 Day Avg. Volume2,753
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Interpace Diagnostics Group Business Overview & Revenue Model
Company Description
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive geno...
How the Company Makes Money
IDXG primarily makes money by performing diagnostic testing services and recognizing revenue when it delivers test results for patient specimens processed through its laboratory operations. Key revenue streams generally include (1) reimbursement f...
Interpace Diagnostics Group Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
66
Positive
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Interpace Diagnostics Group Technical Analysis
Negative
1.46
Price Trends
7.78
Negative
8.51
Negative
8.08
Negative
Market Momentum
-0.29
Positive
40.71
Neutral
24.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXGD, the sentiment is Negative. The current price of 1.46 is below the 20-day moving average (MA) of 7.66, below the 50-day MA of 7.78, and below the 200-day MA of 8.08, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 40.71 is Neutral, neither overbought nor oversold. The STOCH value of 24.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDXGD.
Interpace Diagnostics Group Risk Analysis
Interpace Diagnostics Group disclosed 63 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Interpace Diagnostics Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.01B | -49.90 | -4.15% | ― | 3.18% | -100.37% | |
69 Neutral | $3.42B | 29.53 | 8.64% | ― | 17.28% | 323.64% | |
63 Neutral | $38.30M | 0.05 | 142.98% | ― | -20.48% | 537.47% | |
60 Neutral | $2.23B | -8.76 | -6.31% | 0.75% | 11.19% | 50.58% | |
60 Neutral | $21.66B | -46.25 | 211.46% | ― | 42.74% | -4.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $305.12M | -2.67 | -32.59% | 13.45% | -3.16% | 72.02% |
* Healthcare Sector Average
IDXGD
Interpace Diagnostics Group
6.91
2.84
69.95%
MYGN
Myriad Genetics
3.19
-3.72
-53.84%
VCYT
Veracyte
42.53
10.07
31.02%
NEO
NeoGenomics
17.38
9.45
119.17%
GH
Guardant Health
161.41
101.25
168.28%
CSTL
Castle Biosciences
32.91
8.85
36.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.